Elevated serum vascular endothelial growth factor in patients with hormone‐escaped prostate cancer

Jones, Adam; Fujiyama, Chisato; Turner, Kevin; Fuggle, S; Cranston, David; Bicknell, Roy; Harris, Adrian L.

doi:10.1046/j.1464-410x.2000.00432.x

Cited by 49 publications

(34 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Details for each of these studies are given in Supplementary Table S1 for breast cancer (Yamamoto et al, 1996;Obermair et al, 1997;Salven et al, 1997Salven et al, , 1999bVerheul et al, 1997;Eppenberger et al, 1998;Adams et al, 2000;Foekens et al, 2001;Heer et al, 2001;Colleoni et al, 2002;Toi et al, 2002;Caine et al, 2003;Manders et al, 2003;Desruisseau et al, 2004;Granato et al, 2004;Sancak et al, 2004;Zhao et al, 2004;Bando et al, 2005;O'Riain et al, 2005), Supplementary Table S2 for prostate cancer (Joseph et al, 1997;Salven et al, 1997;Bauer et al, 1999;Duque et al, 1999;Jones et al, 2000;Bok et al, 2001;Figg et al, 2001;Caine et al, 2003Caine et al, , 2004Kohli et al, 2003;George et al, 2004;Kaushal et al, 2005;Li et al, 2005), Supplementary Table S3 for colorectal cancer (Dirix et al, 1996;Hyodo et al, 1998;Kumar et al, 1998;Baker et al, 2000;Chin et al, 2000;Davies et al, 2000;George et al, 2000;Broll et al, 2001;...…”

Section: Study Selectionmentioning

confidence: 99%

Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer

2007

View full text Add to dashboard Cite

Vascular endothelial growth factor (VEGF) is a major target for the inhibition of tumour vascularisation and the treatment of human cancer. Many tumours produce large quantities of VEGF, and as a result, diagnosis and prognosis of cancer may be predicted by measuring changes in VEGF concentrations in blood. In blood, the VEGF may be located in the plasma, or in the blood-borne cells and formed elements, in particular, platelets and leukocytes. In this study, we collate the measurements of VEGF in platelets, leukocytes, plasma and serum for breast, prostate, colorectal and other cancers. In addition, we analysed the concentration of VEGF in tumour tissue itself, as well as for other tissues in the human body. Although the concentration of VEGF in tumours is high, the size of tumours is small compared to other tissues, in particular, skeletal muscle. Thus, the total quantity of VEGF in tumours and in blood is small compared to the quantity in muscles. This large reservoir of VEGF may have important implications for the treatment of cancer.

show abstract

Section: Study Selectionmentioning

confidence: 99%

Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer

2007

View full text Add to dashboard Cite

show abstract

“…The density of new vessel growth is associated with clinically aggressive prostate cancer and disease progression (23). It has been reported that higher levels of VEGF are present in the serum and plasma of men with prostate cancer compared with healthy controls, and increased VEGF levels are associated with metastatic disease and biochemical progression (24,25). A recent meta-analysis has shown that VEGF levels in serum or plasma are ∼2.18 and 1.85 times greater (weighted average of all cancer studies analyzed), respectively, in prostate cancer patients versus healthy controls (26).…”

mentioning

confidence: 99%

Tea Polyphenols Decrease Serum Levels of Prostate-Specific Antigen, Hepatocyte Growth Factor, and Vascular Endothelial Growth Factor in Prostate Cancer Patients and Inhibit Production of Hepatocyte Growth Factor and Vascular Endothelial Growth Factor In vitro

McLarty

Bigelow

Smith

et al. 2009

Cancer Prevention Research

229

167

View full text Add to dashboard Cite

The purpose of this study was to determine the effects of short-term supplementation with the active compounds in green tea on serum biomarkers in patients with prostate cancer.Twenty-six men with positive prostate biopsies and scheduled for radical prostatectomy were given daily doses of Polyphenon E, which contained 800 mg of (−)-epigallocatechin-3-gallate (EGCG) and lesser amounts of (−)-epicatechin, (−)-epigallocatechin, and (−)-epicatechin-

show abstract

“…Other studies (7)(8)(9)(10)13,14) showed higher VEGF levels in patients with prostate cancer when compared with healthy controls or subjects with benign prostatic hypertrophy. Such comparisons however, are not clinically relevant since elevated tPSA is the most frequent indication for prostatic biopsy, and reflect limited-challenge-bias (16,17).…”

Section: Commentsmentioning

confidence: 97%

“…Some authors have found higher levels of VEGF in prostatic cancer patients (7)(8)(9)(10), while others found no differences between subjects with benign prostatic hyperplasia (BPH) and those with malignant disease (11,12), or increased values only in patients with metastatic prostatic cancer (13) or hormonerefractory disease (14). However, most previous studies evaluated relatively small samples (8,9,(11)(12)(13)(14) and all suffered from limited-challenge bias, as prostatitis, which may interfere with the diagnostic value of VEGF, was not evaluated separately in any of the studies and in many studies the control group only included subjects with no suspicion of prostatic cancer (7,10,13).…”

Section: Vascular Endothelial Growth Factor (Vegf)mentioning

confidence: 99%

Vascular endothelial growth factor (VEGF) and prostate pathology

et al. 2010

View full text Add to dashboard Cite

Purpose: Previous studies suggest that vascular endothelial growth factor (VEGF) circulating levels might improve identification of patients with prostate cancer but results are conflicting. Our aim was to compare serum VEGF levels across different prostate pathologies (including benign prostatic hyperplasia, prostatitis, high grade prostate intraepithelial neoplasia and prostate cancer) in patients at high risk of prostate cancer. Materials and Methods:We consecutively enrolled 186 subjects with abnormal digital rectal examination and/or total PSA (tPSA) ≥ 2.5 ng/mL. Blood was collected before diagnostic ultrasound guided trans-rectal prostate biopsy, or any prostate oncology treatment, to measure PSA isoforms and VEGF. Unconditional logistic regression was used to compute age-, tPSA-and free/total PSA-adjusted odds ratios (OR) and respective 95% confidence intervals (95% CI) for the association between serum VEGF and different prostatic pathologies. Results: Prostate biopsy main diagnoses were normal or benign prostatic hyperplasia (27.3%), prostatitis (16.6%), and prostatic cancer (55.0%). The median VEGF levels (ng/mL) in these groups were 178.2, 261.3 and 266.4 (p = 0.029), respectively, but no significant differences were observed for benign vs. malignant pathologies (215.2 vs. 266.4, p = 0.551). No independent association was observed between VEGF (3rd vs. 1st third) and prostate cancer, when compared to benign conditions (adjusted OR = 1.44; CI 95%: 0.64-3.26). Conclusions: In patients at high risk of prostate cancer, circulating VEGF levels have no clinical role in deciding which patients should be submitted to prostate biopsy. Prostatitis patients, often with higher PSA levels, also present high serum levels of VEGF, and their inclusion in control groups might explain the heterogeneous results in previous studies.

show abstract

Elevated serum vascular endothelial growth factor in patients with hormone‐escaped prostate cancer

Cited by 49 publications

References 34 publications

Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer

Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer

Tea Polyphenols Decrease Serum Levels of Prostate-Specific Antigen, Hepatocyte Growth Factor, and Vascular Endothelial Growth Factor in Prostate Cancer Patients and Inhibit Production of Hepatocyte Growth Factor and Vascular Endothelial Growth Factor In vitro

Vascular endothelial growth factor (VEGF) and prostate pathology

Contact Info

Product

Resources

About